[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 145, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 650173, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen J. Elledge Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomasz  Kula Ph.D.", "title": "Co-Founder & Member of Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leiden  Dworak M.B.A.", "title": "VP of Finance & Principal Accounting Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  McCue Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Heather  Savelle", "title": "Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zoran  Zdraveski J.D., Ph.D.", "age": 53, "title": "Chief Legal Officer & Company Secretary", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior Vice President of Medical & Translational Medicine", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Debora  Barton M.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.85, "open": 5.98, "dayLow": 5.76, "dayHigh": 6.1, "regularMarketPreviousClose": 5.85, "regularMarketOpen": 5.98, "regularMarketDayLow": 5.76, "regularMarketDayHigh": 6.1, "beta": 0.74, "forwardPE": -4.983333, "volume": 216139, "regularMarketVolume": 216139, "averageVolume": 126063, "averageVolume10days": 185720, "averageDailyVolume10Day": 185720, "bidSize": 1200, "askSize": 1100, "marketCap": 285991712, "fiftyTwoWeekLow": 1.62, "fiftyTwoWeekHigh": 7.15, "priceToSalesTrailing12Months": 16.889606, "fiftyDayAverage": 5.122, "twoHundredDayAverage": 3.22009, "currency": "USD", "enterpriseValue": 157551584, "floatShares": 23129450, "sharesOutstanding": 43548100, "sharesShort": 354698, "sharesShortPriorMonth": 416028, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.0074, "heldPercentInsiders": 0.00821, "heldPercentInstitutions": 0.68823, "shortRatio": 2.19, "shortPercentOfFloat": 0.0093, "impliedSharesOutstanding": 5143130, "bookValue": 3.533, "priceToBook": 1.6926125, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -88328000, "trailingEps": -2.02, "forwardEps": -1.2, "enterpriseToRevenue": 9.304, "enterpriseToEbitda": -1.85, "52WeekChange": 2.5240965, "SandP52WeekChange": 0.1985048, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "messageBoardId": "finmb_583057578", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.98, "targetHighPrice": 15.0, "targetLowPrice": 7.0, "targetMeanPrice": 10.8, "targetMedianPrice": 9.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 215423008, "totalCashPerShare": 4.504, "ebitda": -85185000, "totalDebt": 86983000, "quickRatio": 6.498, "currentRatio": 6.563, "totalRevenue": 16933000, "debtToEquity": 51.481, "revenuePerShare": 0.354, "returnOnAssets": -0.24831, "returnOnEquity": -0.6185, "grossProfits": -46284000, "freeCashflow": -38036000, "operatingCashflow": -53602000, "revenueGrowth": 0.156, "operatingMargins": -6.36686, "financialCurrency": "USD", "trailingPegRatio": null}]